FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809822839> ?p ?o ?g. }

• W2809822839 endingPage "382" @default.
• W2809822839 startingPage "381" @default.
• W2809822839 abstract "Over the past decade, there has been rapid evolution and expansion in scientific and community interest in HIV curative strategies. The initial report of the cure of Timothy Brown (The Berlin Patient) following CCR5 Δ32/Δ32 stem-cell transplantation in 2009 [1] was a major catalyst in bringing together various stake-holders, including government funding agencies, private foundations, community and advocacy groups, ethicists, regulatory agencies, pharmaceutical companies, scientists and clinicians, to work towards the goal of achieving a sterilizing cure or durable control of HIV after stopping antiretroviral therapy (ART). Dedicated funding opportunities provided support for those working towards these challenging goals, leading to an exponential increase in the number of scientific articles, public articles and media coverage. The status of these efforts was extensively summarized by the International AIDS Society global strategy towards an HIV cure in 2016 [2]. Although additional cases such as Timothy Brown have yet to materialize, the HIV cure field has rapidly expanded to include work on discovering biomarkers of persistent HIV infection, development and implementation of immunological approaches to controlling HIV following ART cessation, cell and gene therapy approaches, early initiation of ART, latency promoting or reversing strategies and development of novel assays to locate, quantify and characterize persistent HIV reservoirs. Although working towards an HIV cure has been met with many scientific and practical challenges, there has been recent, palpable progress. For example, durable control of simian immunodeficiency virus (SIV) has recently been reported in nonhuman primate studies including the use of therapeutic HIV vaccine combined with Toll-like receptor agonists and mAbs directed towards viral envelope proteins or α4β7 integrin, to name just a few [3–5]. Additional cases of prolonged HIV remission prior to viral recrudescence, sometimes lasting many months, have been reported in small, proof-of-concept human studies, although none have lead to unequivocal, sustained HIV cure [6,7]. Work on other strategies has also accelerated, including the search for biomarkers of residual HIV-infected cells or the development of clinical trials incorporating combination therapies to target or modulate various aspects of HIV persistence. Of course, there have been, and always will be, growing pains and false starts while embarking upon novel and innovative cure science, but there is no disputing that the past decade has seen a dramatic increase in the understanding of HIV persistence. However, there are several fundamental questions within HIV curative persistence research that remain unclear. Defining what is meant by an HIV ‘cure’ has undergone several iterations with an emerging consensus that achieving control of HIV following cessation of ART will require immune control in addition to reservoir reduction. This is different from a ‘sterilizing’ cure achieved with Timothy Brown, but nonetheless offers the hope of reducing or eliminating the need for life-long ART. Other questions remain. For example, how do we define HIV latency, and what specifically defines and makes up the viral reservoir? Are all infected cells that remain in the setting of ‘suppressive’ ART important to identify and target, regardless of the degree of transcriptional or translational activity? What level of reservoir reduction will be required to allow immune or other control of HIV replication following treatment interruption? What is the total body distribution and activity of persistently infected cells? Regardless of these ongoing questions, a more robust framework now exists on which HIV eradication and control studies can be designed and evaluated. In several other infectious disease contexts, alternative therapeutic approaches are also urgently needed to circumvent failures or insufficiencies associated with existing antimicrobial agents [6,7]. Lessons for achieving an HIV cure must be drawn from the evolution of these therapeutic strategies and those developed in the fields of oncology and solid organ and stem cell transplantation. For example, immunosuppressive agents such as rapamycin may have unexpected positive impacts on tuberculosis (TB) or HIV infection, and other drugs that are already clinically approved and ready to enter clinical trials, such as metformin, may also have potential impact on TB infection. Immune checkpoint blockade is another example of an immune modifying therapy primarily developed for various cancers that may have some beneficial impact on HIV infection in certain individuals, but also carries significant potential risks. In this issue of Current Opinion in HIV and AIDS, experts in HIV persistence and eradication efforts cover recent findings in topics such as biomarkers of HIV reservoirs, genital reservoirs, posttreatment control of HIV infection, therapeutic vaccination, mathematical approaches to understanding persistence and viral eradication, immunomodulatory therapies for HIV, chimeric antigen receptor T-cell approaches and analytical treatment interruptions. Ethical and clinical issues of trials to achieve functional cure are also addressed which are critical to achieving a well tolerated and scalable HIV cure. In contrast to standard antiretrovirals, which are well tolerated, many HIV curative strategies are not devoid of potential deleterious effects. Moreover, treatment interruptions alone as a means of assessing the effectiveness of these strategies may also carry risks, including viral recrudescence and exposure to secondary transmission risks. The establishment of clinical cure trials leads to a paradigm shift in the management of HIV of which participants, clinicians and researchers must be aware. Clearly, the HIV curative field is much larger and more involved than what can be summarized in just a few articles, but the breadth and depth of the research presented attests to the importance and durability of searching for a cure. Although progress towards HIV cure has yet to achieve the number or breath of these successes, it is much easier to be an optimist in this exciting era of scientific and community research. However, momentum will only continue if there are continued interest and support from all parties involved. Acknowledgements None. Financial support and sponsorship T.J.H. is supported by NIH/NIAID R01AI122862 and R33AI116205. Conflicts of interest T.J.H. provides consulting services to Merck and receives grant support from Gilead Biosciences." @default.
• W2809822839 created "2018-07-10" @default.
• W2809822839 creator A5004908163 @default.
• W2809822839 creator A5063249733 @default.
• W2809822839 date "2018-09-01" @default.
• W2809822839 modified "2023-10-18" @default.
• W2809822839 title "Progress towards obtaining an HIV cure" @default.
• W2809822839 cites W2124058652 @default.
• W2809822839 cites W2466398959 @default.
• W2809822839 cites W2531054429 @default.
• W2809822839 cites W2556485149 @default.
• W2809822839 cites W2597074085 @default.
• W2809822839 cites W2767453022 @default.
• W2809822839 cites W2769329598 @default.
• W2809822839 doi "https://doi.org/10.1097/coh.0000000000000492" @default.
• W2809822839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29965799" @default.
• W2809822839 hasPublicationYear "2018" @default.
• W2809822839 type Work @default.
• W2809822839 sameAs 2809822839 @default.
• W2809822839 citedByCount "3" @default.
• W2809822839 countsByYear W28098228392020 @default.
• W2809822839 countsByYear W28098228392022 @default.
• W2809822839 countsByYear W28098228392023 @default.
• W2809822839 crossrefType "journal-article" @default.
• W2809822839 hasAuthorship W2809822839A5004908163 @default.
• W2809822839 hasAuthorship W2809822839A5063249733 @default.
• W2809822839 hasBestOaLocation W28098228391 @default.
• W2809822839 hasConcept C138885662 @default.
• W2809822839 hasConcept C142462285 @default.
• W2809822839 hasConcept C177713679 @default.
• W2809822839 hasConcept C203014093 @default.
• W2809822839 hasConcept C2778025104 @default.
• W2809822839 hasConcept C2778137410 @default.
• W2809822839 hasConcept C2993143319 @default.
• W2809822839 hasConcept C3013748606 @default.
• W2809822839 hasConcept C41895202 @default.
• W2809822839 hasConcept C71924100 @default.
• W2809822839 hasConceptScore W2809822839C138885662 @default.
• W2809822839 hasConceptScore W2809822839C142462285 @default.
• W2809822839 hasConceptScore W2809822839C177713679 @default.
• W2809822839 hasConceptScore W2809822839C203014093 @default.
• W2809822839 hasConceptScore W2809822839C2778025104 @default.
• W2809822839 hasConceptScore W2809822839C2778137410 @default.
• W2809822839 hasConceptScore W2809822839C2993143319 @default.
• W2809822839 hasConceptScore W2809822839C3013748606 @default.
• W2809822839 hasConceptScore W2809822839C41895202 @default.
• W2809822839 hasConceptScore W2809822839C71924100 @default.
• W2809822839 hasIssue "5" @default.
• W2809822839 hasLocation W28098228391 @default.
• W2809822839 hasLocation W28098228392 @default.
• W2809822839 hasLocation W28098228393 @default.
• W2809822839 hasOpenAccess W2809822839 @default.
• W2809822839 hasPrimaryLocation W28098228391 @default.
• W2809822839 hasRelatedWork W1973460911 @default.
• W2809822839 hasRelatedWork W2096903645 @default.
• W2809822839 hasRelatedWork W2115165681 @default.
• W2809822839 hasRelatedWork W2369589320 @default.
• W2809822839 hasRelatedWork W2520411286 @default.
• W2809822839 hasRelatedWork W2593570428 @default.
• W2809822839 hasRelatedWork W2887187324 @default.
• W2809822839 hasRelatedWork W2915885685 @default.
• W2809822839 hasRelatedWork W4322484426 @default.
• W2809822839 hasRelatedWork W2522518582 @default.
• W2809822839 hasVolume "13" @default.
• W2809822839 isParatext "false" @default.
• W2809822839 isRetracted "false" @default.
• W2809822839 magId "2809822839" @default.
• W2809822839 workType "article" @default.